eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
4/2017
vol. 21
 
Share:
Share:
more
 
 
abstract:
Original paper

Efficacy of palifermin on oral mucositis and acute GVHD after hematopoietic stem cell transplantation (HSCT) in hematology malignancy patients: a meta-analysis of trials

Hamid Reza Mozaffari, Mehrdad Payandeh, Mazaher Ramezani, Masoud Sadeghi, Mohammad Mahmoudiahmadabadi, Roohollah Sharifi

Contemp Oncol (Pozn) 2017; 21 (4): 299-305
Online publish date: 2017/12/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Aim of the study: Herein, this meta-analysis study evaluated the efficacy of palifermin after HSCT on the incidence and severity of OM or aGVHD in hematologic malignancy patients in randomized clinical trials (RCTs).

Materials and methods: To compare the efficacy of palifermin on adverse events, OM and aGVHD compared with placebo, we searched databases of PubMed/Medline, Web of Science and Cochrane Library for RCTs based on a number of criteria.

Results: There was no difference observed in the incidence of OM and aGVHD between two groups. The subgroup analysis didn’t show significant differences in two groups for aGVHD grade 2–4 (odds ratio [OR] = 1.54, 95% confidence interval (CI): 0.70–3.39, p = 0.28), aGVHD grade 3–4 (OR = 0.97, 95% CI: 0.48–1.94, p = 0.92), OM grade 2–4 (OR = 0.76, 95% CI: 0.42–1.38, p = 0.37) and OM grade 3–4 (OR = 0.54, 95% CI: 0.25–1.15, p = 0.11], but erythema as an adverse effect in palifermin group was higher than placebo group (OR = 1.86, 95% CI: 1.10–3.15, p = 0.02].

Conclusions: This meta-analysis of six clinical trials found no statistically significant difference in OM and aGVHD grades in patients receiving 60 µg/kg/day dose of palifermin compared with those receiving a placebo. However, oral mucosal erythema was more prevalent among patients receiving palifermin than patients receiving a placebo.
keywords:

palifermin, hematopoietic cell transplantation, hematology malignancy, adverse event, meta-analysis

references:
Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ. Patient reports of complications of bone marrow transplantation. Support Care Cancer 2000; 8: 33-9.
Peterson DE, Cariello A. Mucosal damage: a major risk factor for severe complications after cytotoxic therapy. Semin Oncol 2004; 31: 35-44.
Cutler C, Li S, Kim HT, et al. Mucositis after hematopoietic stem cell transplantation: a cohort study of methotrexate- and non–methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005; 11: 383-8.
Gabriel DA, Shea T, Olajida O, Serody JS, Comeau T. The effect of oral mucositis on morbidity and mortality in bone marrow transplant. Semin Oncol 2003; 30: 76-83.
Lark RL, McNeil SA, VanderHyde K, Noorani Z, Uberti J, Chenoweth C. Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients. Clin Infect Dis 2001; 33: 338-43.
McGuire DB, Rubenstein EB, Peterson DE. Evidence-based guidelines for managing mucositis. Sem Oncol Nurs 2004; 20: 59-66.
Dodd MJ. The pathogenesis and characterization of oral mucositis associated with cancer therapy. Oncol Nurs Forum 2004; 31: 5-11.
Farrell CL, Rex KL, Chen JN. The effects of keratinocyte growth factor in preclinical models of mucositis. Cell Prolif 2002; 35: S78-S85.
Brosa M, Arocho R. Cost-effectiveness of the prevention of oral mucositis (OM) with Kepivance® (palifermin) in patients undergoing myeloablative therapy with autologous stem cell transplantation (ASCT) in Spain. Value in Health 2006; 9: A282.
Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-8.
Okada EM, Ribeiro LN, Stuani MB, et al. Effects of chlorhexidine varnish on caries during orthodontic treatment: a systematic review and meta-analysis. Braz Oral Res 2016; 30: e115.
Fowkes FG, Fulton PM. Critical appraisal of published research: introductory guidelines. BMJ 1991; 302: 1136-40.
Egger M, Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
Blazar BR, Weisdorf DJ, Defor T, et al. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 2006; 108: 3216-22.
Blijlevens N, de Château M, Krivan G, et al. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient’s burden. Bone Marrow Transplant 2013; 48: 966-71.
Jagasia MH, Abonour R, Long GD, et al. Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial. Bone Marrow Transplant 2012; 47: 1350-5.
Lucchese A, Matarese G, Ghislanzoni LH, Gastaldi G, Manuelli M, Gherlone E. Efficacy and effects of palifermin for the treatment of oral mucositis in patients affected by acute lymphoblastic leukemia. Leuk Lymphoma 2016; 57: 820-7.
Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590-8.
Lucchese A, Matarese G, Manuelli M, et al. Reliability and efficacy of palifermin in prevention and management of oral mucositis in patients with acute lymphoblastic leukemia: a randomized, double-blind controlled clinical trial. Minerva Stomatol 2016; 65: 43-50.
Blijlevens N, Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol 2007; 18: 817-26.
Meropol NJ, Somer RA, Gutheil J, et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 2003; 21: 1452-8.
Abidi MH, Agarwal R, Tageja N, et al. A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by slogous stem cell transplantation for patients with multiple myeloma with normal renal function. Biol Blood Marrow Transplant 2013; 19: 56-61.
Fliedner M, Baguet B, Blankart J, et al. Palifermin for patients with haematological malignancies: shifting nursing practice from symptom relief to prevention of oral mucositis. Eur J Oncol Nurs 2007; 11: S19-26.
Goldberg JD, Zheng J, Castro-Malaspina H, et al. Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant 2013; 48: 99-104.
Panoskaltsis-Mortari A, Lacey DL, Vallera DA, et al. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 1998; 92: 3960-7.
Alpdogan O, Hubbard VM, Smith OM, et al. Keratinocyte growth factor (KGF) is required for postnatal thymic regeneration. Blood 2006; 107: 2453-60.
Rossi S, Blazar BR, Farrell CL, et al. Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft versus-host disease. Blood 2002; 100: 682-91.
Nasilowska-Adamska B, Rzepecki P, Manko J, et al. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant. Bone Marrow Transplant 2007; 40: 983-8.
Langner S, Staber P, Schub N, et al. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant 2008; 42: 275-9.
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe